Navigation Links
BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones
Date:1/10/2014

RALEIGH, N.C., Jan. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced updates to the company's anticipated 2014 milestones for its product portfolio, including the imminent database lock for the Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in opioid naive subjects, with topline data expected late January or early February.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals.  This event is expected to trigger a $10 million milestone payment from Endo per the licensing and development agreement signed in January 2012.  

In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter. 

BDSI also continues to develop the commercialization plans for the launch of BUNAVAIL for the maintenance treatment of opioid dependence.  As previously reported, the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of June 7, 2014 for BUNAVAIL, which if approved is anticipated to launch late third quarter 2014.  BDSI estimates annual peak U.S. sales of BUNAVAIL of up to $250 million.

"This year will potentially provide two of the most significant value driving milestones that our company has ever experienced," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "We look forward
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
2. BioDelivery Sciences to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials
4. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
5. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
7. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
8. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
9. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
10. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
11. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... ATLANTA, Feb. 3 Brent McKenzie, based ... Consulting, the nation,s fastest growing,pharmacy benefit firm, ... Mr. McKenzie offers his clients over ... Benefits and Pharmacy Benefit Management arena.,Brent has ...
... Cancer Care Access, Efficiency and Quality; Created Based ... 3 /PRNewswire-USNewswire/ -- The National Policy ... the nation,s largest cancer treatment and research networks ... Principles for Reforming Cancer Care, designed to guide ...
... of medical research, study finds , , TUESDAY, Feb. 3 ... white parents to distrust medical research, which may explain ... So conclude University of Pittsburgh researchers who surveyed 190 ... to a primary-care clinic. , The parents were asked ...
... 2009) Green tea products have become regarded as a ... its benefit against a variety of diseases, including cancer. ... tea may counteract the anticancer effects of one cancer ... contraindicated for patients taking this medicine to ensure its ...
... study suggests that Capn4, a protein involved in cell ... after liver transplantation. Capn4 could potentially be used as ... These findings are in the February issue of ... Sons on behalf of the American Association for the ...
... popular assumptions about the health benefits of green tea, ... found that the widely used supplement renders a cancer ... lymphoma completely ineffective in treating cancer. , The ... extract (GTE) called EGCG destroys any anticancer activity of ...
Cached Medicine News:Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Parental Distrust May Explain Lack of Black Children in Clinical Trials 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:Protein predicts liver cancer recurrence and after transplantation 2Health News:USC study finds that green tea blocks benefits of cancer drug 2
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: